Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.

Yildiz, İBRAHİM; Sen, Fatma; Basaran, Mert; Ekenel, Meltem; Agaoglu, FULYA; Darendeliler, Emin; Tunc, Hayri; Ozcan, Faruk; Bavbek, Sevil

doi:10.1093/jjco/hyr151

Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.

Atıf İçin Kopyala

Yildiz İ., Sen F., Basaran M., Ekenel M., Agaoglu F., Darendeliler E., ...Daha Fazla

Japanese journal of clinical oncology, cilt.41, sa.12, ss.1380-7, 2011 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 41 Sayı: 12
Basım Tarihi: 2011
Doi Numarası: 10.1093/jjco/hyr151
Dergi Adı: Japanese journal of clinical oncology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1380-7
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Objective: Therapy targeted against the vascular endothelial growth factor pathway is a standard of care for patients with metastatic renal cell carcinoma. This study assessed the response rates and toxicity profiles of sunitinib on a continuous once-daily dosing regimen in Turkish patients with metastatic renal cell carcinoma.